Terms: = Kidney tumors AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155 AND Treatment
50 results:
1. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract] [Full Text] [Related]
2. pbrm1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma.
Sellner F; Compérat E; Klimpfinger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003482
[TBL] [Abstract] [Full Text] [Related]
4. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
5. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract] [Full Text] [Related]
6. Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.
Deutsch JS; Lipson EJ; Danilova L; Topalian SL; Jedrych J; Baraban E; Ged Y; Singla N; Choueiri TK; Gupta S; Motzer RJ; McDermott D; Signoretti S; Atkins M; Taube JM
Cell Rep Med; 2023 Feb; 4(2):100947. PubMed ID: 36812889
[TBL] [Abstract] [Full Text] [Related]
7. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
Rustum YM; Reis R; Rustum TM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674417
[TBL] [Abstract] [Full Text] [Related]
8. The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.
Langbein LE; El Hajjar R; Kim WY; Yang H
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1417-C1429. PubMed ID: 36154696
[TBL] [Abstract] [Full Text] [Related]
9. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract] [Full Text] [Related]
10. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Kotecha RR; Gedvilaite E; Ptashkin R; Knezevic A; Murray S; Johnson I; Shapnik N; Feldman DR; Carlo MI; Shah NJ; Dunigan M; Huberman K; Benayed R; Zehir A; Berger MF; Ladanyi M; Tsui DWY; Motzer RJ; Lee CH; Voss MH
JCO Precis Oncol; 2022 Jul; 6():e2200012. PubMed ID: 35797508
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang N; Qin Y; Du F; Wang X; Song C
Gene; 2022 Aug; 834():146638. PubMed ID: 35680019
[TBL] [Abstract] [Full Text] [Related]
12. The RBPJ/DAPK3/UBE3A signaling axis induces pbrm1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors.
Liu W; Zhang B; Zhang D; Guo F; Ye K; Zhu L; Jin X
Cell Death Dis; 2022 Apr; 13(4):295. PubMed ID: 35368029
[TBL] [Abstract] [Full Text] [Related]
13. T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.
Lee MH; Järvinen P; Nísen H; Brück O; Ilander M; Uski I; Theodoropoulos J; Kankainen M; Mirtti T; Mustjoki S; Kreutzman A
Oncoimmunology; 2022; 11(1):1993042. PubMed ID: 35003893
[TBL] [Abstract] [Full Text] [Related]
14. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with pbrm1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract] [Full Text] [Related]
15. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract] [Full Text] [Related]
16. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
[TBL] [Abstract] [Full Text] [Related]
17. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E; Walker CL; Rathmell WK
Nat Rev Nephrol; 2021 Apr; 17(4):245-261. PubMed ID: 33144689
[TBL] [Abstract] [Full Text] [Related]
18. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
Hakimi AA; Attalla K; DiNatale RG; Ostrovnaya I; Flynn J; Blum KA; Ged Y; Hoen D; Kendall SM; Reznik E; Bowman A; Hwee J; Fong CJ; Kuo F; Voss MH; Chan TA; Motzer RJ
Nat Commun; 2020 Aug; 11(1):4168. PubMed ID: 32820162
[TBL] [Abstract] [Full Text] [Related]
19. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.
Dizman N; Lyou Y; Salgia N; Bergerot PG; Hsu J; Enriquez D; Izatt T; Trent JM; Byron S; Pal S
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661119
[TBL] [Abstract] [Full Text] [Related]
20. Immune Checkpoint Inhibitors in the treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract] [Full Text] [Related]
[Next]
